rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Pronostic Value of Fluid Responsiveness Evaluated by Inferior Vena Cava Collapsibility Index in Patients Admitted in ICU With Acute Respiratory Failure
Status: Recruiting

Acute respiratory failure represents a frequent cause of admission to intensive care units (ICUs). In the absence of tailored interventions, it poses an imminent threat to patients' lives. Most patients admitted in ICU undergo fluid expansion to enhance oxygen delivery and preserve cellular function.

This practice is grounded in the concept of " preload responsiveness ". However, the accrual of positive fluid balance resulting from fluid administration is now acknowledged as an autonomous risk factor for mortality.

Consequently, preload unresponsiveness assumes a pathological character, potentially indicative of fluid overload or right ventricular dysfunction, both deleterious conditions linked to unfavorable outcomes.

Maintaining patients in a preload-responsive state may be interesting to limit fluid expansion and the need of invasive mechanical ventilation.

The objective of this prospective observational study is to evaluate the prognostic significance of preload responsiveness in patients admitted to the ICU with hypoxemic, non-hypercapnic respiratory failure.

Main objective: To evaluate the association between fluid responsiveness, assessed by the inferior vena cava collapsibility index (cIVC) with trans-thoracic echocardiography within the initial 48 hours post-ICU admission, and mortality or the need for invasive mechanical ventilation by day 28 in patients admitted to the ICU for hypoxemic, non-hypercapnic acute respiratory failure.
Secondary objectives: To evaluate the association between fluid responsiveness and mortality at day 28 and day 90, the need of invasive mechanical ventilation, and the number of days free from organ support (vasopressors, mechanical ventilation and renal replacement therapy) by day 28.

Upon receipt of both oral and written information, patients will provide non-objection to participate in the study. This prospective single-center study has obtained approval from the Regional Ethics Committee of Ile de France III approval (No. 2022-A02813-40).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age > 18 years Registered in the French National Health Insurance system  Presenting all the following criteria:  Admission in ICU for less than 48 hours Type 1 acute respiratory failure: hypoxemia (PaO2< 60 mmHg on room air) without hypercapnia (PaCO2 < 45 mmHg) Requiring oxygen support of ≥ 5L./min Necessitating transthoracic echocardiography for diagnostic purposes  Exclusion Criteria:  Pregnancy Adult with disability or without social protection BMI > 35 kg/m² Withhold decision regarding invasive mechanical ventilation Moribund state diagnosed as a SOFA score > 20 - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: This is a monocentric observational study performed in the University Hospital of Lille, among adult patients admitted in ICU for hypoxemic and non hypercapnic acute respiratory failure for less than 48 hours - SamplingMethod: Non-Probability Sample
YOD-RiSoCo: Social Cognition and Risky Decision-making in Patients With Young-onset Dementia
Status: Not yet recruiting

The goal of this observational study is to learn about social cognition and risky behaviour in patients with young-onset dementia (YOD). The investigators want to

Examine differences in performance on social cognition test and measures of risky behaviour between behavioural variant YOD patients, patients with frontal brain injury, non-behavioural YOD patients and healthy controls.
Examine if there is a relation between social cognition tests and measures of risky behaviour.

Participants will be administered a neuropsychological assessment including social cognition measures and patients will complete a driving simulator task in which risky behaviour will be elicited.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  All subjects  Sufficient command of the Dutch language In possession of a driver's license with any driving experience throughout life Age 18 to 65  bvYOD subjects  Probable diagnosis of young-onset dementia (before 65 years old), confirmed after interdisciplinary consensus meeting in which interviews, neuropsychological examination, neurological and psychiatric assessments, neuro-imaging, blood samples, and in some cases FDG/PIB-PETscans, CSF biomarkers or genetic counseling were discussed. Nosological diagnosis of bvFTD or bvAD  Non-bvYOD subjects  Probable diagnosis of young-onset dementia (before 65 years old), confirmed after interdisciplinary consensus meeting in which interviews, neuropsychological examination, neurological and psychiatric assessments, neuro-imaging, blood samples, and in some cases FDG/PIB-PETscans, CSF biomarkers or genetic counseling were discussed. YOD subtypes other dan bvFTD or bvAD, such as amnestic variant AD.  Frontal brain injury subjects  - Neurological patients with frontal brain injury (e.g. traumatic brain injury, stroke or brain tumor patients).  Exclusion Criteria:  All subjects  Suffering from severe motion sickness; motion sickness is a risk factor for simulator sickness  YOD subjects:  - Presence of premorbid severe neurological or psychiatric pathology, non-related to dementia.  Frontal brain injury subjects:  - Presence of serious psychiatric disorders or other neurological comorbidities.  Healthy control subjects:  Presence of serious psychiatric disorders History of neurological disorders, which may interfere with cognitive functioning (e.g. recent concussion, previous subarachnoid or intracerebral haemorrhage, intracranial tumours, epilepsy, ischemic stroke). - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with young-onset dementia, i.e. onset of dementia before the age of 65 years. - SamplingMethod: Probability Sample
Removal Of CytoKines With cytoSorbenTs After Imflammatory Response Reaction During Cardiac Surgery
Status: Recruiting

Detailed knowledge about the association between systemic inflammation and endothelial progenitor cell (EPCs) activation during extracorporeal circulation (ECC) is lacking.

This pilot study aims to clarify the relationship between CD34-positive EPCs and cytokine release during ECC using the cytokine adsorber to make a predictive statement regarding the clinical expression of inflammation.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  planned cardiac surgical procedure with the use of the cardiopulmonary machine as well as with ECMO use (elective or urgent) age at the time of surgery of &gt;18 years. informed consent  Exclusion Criteria:  An emergency indication; endocarditis, a non-sterile inflammation, autoimmune diseases, chronic inflammatory diseases (ankylosing spondylitis, psoriasis, rheumatoid arthritis, chronic inflammatory intestinal diseases), an acquired immune deficit (HIV); severe liver dysfunction, hepatitis B/0; patients on dialysis; Patients with a hematopoietic disorder/tumour disease; participation in other interventional trials or studies; timely and probable follow-up cannot be guaranteed (e.g. due to long distances between home and study site); a pregnancy that cannot be excluded with certainty (no menopause, no sterilization). - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
Status: Recruiting

Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border, stromal cellularity, stromal atypia, mitotic activity and stromal overgrowth. Malignant PTs account for 18%-25%, with high local recurrence (up to 65%) and distant metastasis rates (16%-25%). Benign PT could progress to malignancy after multiple recurrences. Therefore, Early, accurate diagnosis and identification of therapeutic targets are crucial for improving outcomes and survival rates.

In recent years, there has been growing interest in the application of artificial intelligence (AI) in medical diagnostics. AI can integrate clinical information, histopathological images, and multi-omics data to assist in pathological and clinical diagnosis, prognosis prediction, and molecular profiling.AI has shown promising results in various areas, including the diagnosis of different cancers such as colorectal cancer, breast cancer, and prostate cancer. However, PT differs from breast cancer in diagnosis and treatment approach. Therefore, establishing an AI-based system for the precise diagnosis and prognosis assessment of PT is crucial for personalized medicine.

The research team, led by Dr. Nie Yan, is one of the few in Guangdong Province and even nationally, specializing in PT research. Their team has been conducting research on the malignant progression, metastasis mechanisms, and molecular markers for PT. The team has identified key mechanisms, such as fibroblast-to-myofibroblast differentiation, and the role of tumor-associated macrophages in promoting this differentiation. They have also identified molecular markers, including miR-21, α-SMA, CCL18, and CCL5, which are more accurate in predicting tumor recurrence risk compared to traditional histopathological grading.

The project has collected high-quality data from nearly a thousand breast PT patients, including imaging, histopathology, and survival data, and has performed transcriptome gene sequencing on tissue samples. They aim to build a comprehensive multi-omics database for breast PT and create an AI-based model for early diagnosis and prognosis prediction. This research has the potential to improve the diagnosis and treatment of breast PT, address the disparities in breast PT care across different regions in China, and contribute to the development of new therapeutic targets.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients diagnosed with a phyllodes tumor of the breast  Exclusion Criteria:  Blurred images, imaging artifacts - HealthyVolunteers: No - Gender: Female - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Patients are all those who attended Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. - SamplingMethod: Non-Probability Sample
Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered Room
Status: Not yet recruiting

The goal of this observational study is to comparison of the complications in multiple myeloma patients who received autologous stem cell transplantation between in HEPA-filtered room and non-HEPA-filtered room. The main questions it aims to answer are:

The incidence of febrile neutropenia, infection, and duration of hospital stay
2-year progression free survival Participants will be collected the data of baseline diagnosis, treatment, treatment results and complications during admission and follow-up visits from hospital medical record.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  aged 18 - 65 years old Patients with multiple myeloma undergoing treatment with autologous stem cell transplantation and having a Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) score less than or equal to 2 Patients must provide signed consent to participate in the research if they undergo ASCT after the study has been approved. If patients undergo ASCT before the study approval, retrospective data will be collected.  Exclusion Criteria:  Patients with concomitant other types of cancer Patients who refuse to participate in the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult - StudyPopulation: multiple myeloma patients who received autologous stem cell transplantation - SamplingMethod: Probability Sample
Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease
Status: Not yet recruiting

The goal of this observational study is to register hematologic patients with haploidentical hematopoietic stem cell transplantation (haploHSCT). The main questions it aims to answer are:

1-year progression free survival rate
1-year overall survival rate
Graft-versus-host free relapsed free survival at 30-day, 100-day, 180-day and 1-year
Chronic Graft-versus-host free relapsed free survival at 180-day and 1-year
Rate of Neutrophil and platelet engraftment
Efficacy of donor specific antibody desensitization
Relapsed rate
Primary and late graft failure
Safety and complication of haploHSCT
Complication of viral, bacterial, and fungal infection
Viral reactivation
Comparison outcomes between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT
Comparison cost-effectiveness of treatment between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients diagnosed with hematologic diseases indicated for treatment with haploidentical hematopoietic stem cell transplantation including  Myeloid diseases (acute myeloblastic leukemia, myelodysplastic syndrome, chronic myelocytic leukemia, classical and non-classical myeloproliferative disorders) Lymphoid disease (acute lymphoblastic leukemia, lymphoma) severe aplastic anemia Unable to find a matched sibling donor (MSD) or matched unrelated donor (MUD), and no alternative treatments Eastern Cooperative Oncology Group (ECOG) 0-2 normal AST and ALT, creatinine &lt;2g/dL, and left ventricular ejection fraction ≥50% age &gt;18 years Capable of informed consent and provision of written informed consent before any study procedures Capable of attending all study visits according to the study schedule Female subjects who is childbearing potential must have a negative result for pregnancy test  Exclusion Criteria:  HIV infection, active hepatitis B, active hepatitis C active infection history of other malignancy except basal cell carcinoma and carcinoma of the cervix in situ A pregnant woman and/or refusal of contraception - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: hematologic patients with haploidentical hematopoietic stem cell transplantation - SamplingMethod: Probability Sample
Registry of Patients With Plasma Cell Disorders
Status: Not yet recruiting

The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are:

The incidence of plasma cell disorders both before and after malignancy
Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM)
Progression free survival (PFS)
overall survival
factors influencing overall survival, progression-free survival, and time to progression
Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients.
genetic characteristics of plasma cell disorder
cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group 2014 Aged 18 years and above  Exclusion Criteria:  insufficient data needed for analysis - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: plasma cell disorder patients - SamplingMethod: Non-Probability Sample
Integrative Neuro-social Cognitive Strategy Programme for Instilling REcovery (INSPIRE) a Community-Based Cognitive Remediation Trial
Status: Not yet recruiting

Adults with serious mental illnesses (such as schizophrenia and schizoaffective disorders) often experience a range of cognitive difficulties (such as memory, problem solving difficulties) that affect their ability to lead meaningful life roles. Cognitive remediation is an intervention to address cognitive difficulties in this group of mental health service users. Its implementation in less well-resourced community-based settings is less well-studied.

Therefore, the aims of the study are:

To investigate the effects of cognitive remediation on various cognitive skills (such as attention, memory, problem-solving, facial expression recognition, taking others' perspectives etc), for participants with schizophrenia or schizoaffective disorders in community mental health settings.
To investigate if factors such as participants' motivation for engagement and social interaction can affect changes in cognitive skills and functional ability.

Participants in the treatment group will attend computer-based cognitive exercises to improve their cognitive skills. They will also participate in group sessions facilitated by therapists to learn how to utilize strategies learned from the computer sessions in their daily lives. Participants in the control group will attend the usual rehabilitation activities in their respective community-based psychiatric rehabilitation centers.

This research study will compare the differences in their cognitive performance, functional ability and recovery immediately after the intervention and 8 weeks later.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  A diagnosis of schizophrenia or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-V). Able to converse in English and understand English instructions, as the cognitive games and bridging groups will be conducted in English.  Exclusion Criteria:  Known neurological diseases and epilepsy, which affects gains from cognitive remediation. Unable to speak and understand English. Global Assessment of Functioning score of 30 or below, as participants who are too low functioning are unable to benefit from a strategy learning approach. - HealthyVolunteers: No - Gender: All - MinimumAge: 21 Years - MaximumAge: 60 Years - StdAgeList: Adult
Trazodone on OSA Endotypes
Status: Recruiting

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Some OSA patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this protocol the investigators will test the effect of trazodone administered before sleep on OSA traits and OSA severity during sleep.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Moderate-to-severe OSA (AHI ≥ 15 events/hr)  Exclusion Criteria:  All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements. Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid). Use of SNRIs/SSRIs. Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition. Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea: Other sleep disorders: periodic limb movements (periodic limb movement arousal index > 10/hr), narcolepsy, or parasomnias. Hypersensitivity to the study drug (angioedema or urticaria) Contraindications to DAW2020 Use of medications that lengthen QTc interval Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease Severe claustrophobia. - HealthyVolunteers: No - Gender: All - MinimumAge: 21 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients
Status: Recruiting

This study is being done in order to understand what causes people to have a chronic cough, which is defined as a cough lasting for more than 8 weeks. The research team wish to find out whether there is any inflammation in the lungs of patients with chronic cough. The research team will also determine whether a suspected chemical produced in the body, called adenosine triphosphate (ATP) can be responsible for causing the chronic cough. In order to be able to find out what is abnormal in those who have a chronic cough, The research team will need to compare their results with those that do not have a chronic cough.

In this study, the research team will examine 10 participants who suffer from chronic cough and 8 individuals who do not have a chronic cough and are healthy.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  - 1. For Normal non-smoking subject: Healthy individuals, free of significant disease No history of asthma/rhinitis, No therapies, Baseline FEV1 ≥80% predicted with FEV1/FVC ratio >70% Non-smoker for at least the past 12 months with a pack history of ≤5 pack-years  2. For chronic cough participants: History of chronic cough of at least 8 weeks' duration and should have been followed in the Cough Clinic for at least 6 months.  Undergone a protocol with a diagnostic pathway as recommended by the ERS guidelines for management of cough.  Would have either an identifiable cause for their cough that have failed therapies targeted towards the identified cause or classed as having chronic idiopathic cough where no identifiable cause has been found.  3. General Inclusion Criteria: Give written informed consent prior to participation in the study including all of its procedures. Comply with the requirements and restrictions listed in the consent form.  Male or female subject aged between 30 and 70 years old at screening. Able to complete the study and all measurements. Able to read, comprehend, and write at a sufficient level to complete study related materials.  Exclusion Criteria:  - - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 30 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients who suffer from chronic cough and healthy volunteers - SamplingMethod: Non-Probability Sample